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Abstract: SNAI1, a zinc finger transcription factor, not only acts as the master regulator of epithelial-
mesenchymal transition (EMT) but also functions as a driver of cancer progression, including cell
invasion, survival, immune regulation, stem cell properties, and metabolic regulation. The regulation
of SNAI1 occurs at the transcriptional, translational, and predominant post-translational levels
including phosphorylation, acetylation, and ubiquitination. Here, we discuss the regulation and
role of SNAI1 in cancer metastasis, with a particular emphasis on epigenetic regulation and post-
translational modifications. Understanding how signaling networks integrate with SNAI1 in cancer
progression will shed new light on the mechanism of tumor metastasis and help develop novel
therapeutic strategies against cancer metastasis.
Keywords: SNAI1; metastasis; post-translational modifications; epigenetic; EMT
1. Introduction
Tumor metastasis, the spreading of cancer cells from original tumor sites to distant or-
gans followed by development of secondary tumors, is the foremost cause of cancer-related
deaths [1]. Initiation of the metastatic program is often followed by exploitation of an
embryonic development process referred to as epithelial-mesenchymal transition (EMT) [2].
During EMT, epithelial cells attain mesenchymal phenotypes such as increased motility
and invasiveness by dissolving cell–cell junctions and rebuilding cell–matrix connections,
accompanied by loss of epithelial markers and a gain of mesenchymal markers [3]. EMT is
activated by a plethora of EMT-activating transcription factors (EMT-TFs), such as those
from the SNAIL, zinc finger E-box binding homeobox (ZEB), and TWIST families [4].
SNAI1 was the first discovered and most intensively studied transcription repressor
of E-cadherin, a hallmark of EMT encoded by the epithelial gene CDH1. SNAI1 directly
binds to E-boxes present in the CDH1 promoter to transcriptionally repress its expression.
On the other hand, SNAI1 also acts as a transcriptional activator. SNAI1 not only enhances
mesenchymal markers including fibronectin, collagens, and the matrix degradation en-
zyme matrix metalloproteinases 2 and 9 (MMP2 and MMP9), it also increases other EMT
transcription factors such as TWIST and ZEB1 [5,6]. In addition, SNAI1 positively regulates
transcriptional activation of target genes involved in Drosophila development through direct
binding to the promoters [7]. In collaboration with early growth response 1(EGR1) and
SP1, SNAI1 may directly activate transcription of p15INK4b, lymphoid enhancer-binding
factor (LEF), and cyclooxygenase 2 (COX2) by directly binding on a consensus motif in
HepG2 cells stimulated by the phorbol ester tumor promoter 12-O-tetradecanoyl-phorbol
13-acetate (TPA) [5,8–10]. SNAI1 induces resistance to apoptosis, confers tumor recurrence
and drug resistance, generates breast cancer stem cell (CSC)-like properties, and induces
aerobic glycolysis [11–14]. Interestingly, SNAI1 is tightly controlled at both transcrip-
tional and protein levels. Many growth factors and cytokines can transcriptionally regulate
SNAI1 expression [15]. In addition, SNAI1 protein levels are regulated by post-translational
modifications (PTMs). These PTMs have diverse effects on the function of SNAI1.
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Because of the reversible plasticity of EMT, epigenetic alternations are required in the
EMT process. In eukaryotic cells, genomic DNA interacts with histone proteins and RNA
to form chromatin, which holds epigenetic information independent of the DNA genetic
data [16]. Alteration of chromatin occurs through regulators responsible for DNA methyla-
tion, post-translational modifications of nucleosomal histone tails, and/or non-coding RNA
modulation; these epigenetic modifications play a key role in regulating gene expression
by defining whether chromatins at a given genomic locus will be transcriptionally active
or inactive [17]. For EMT, a variety of epigenetic regulators are critical requirements that
interpret signals passed from stimulators to transcription factors [18]. Indeed, the expres-
sion of CDH1 is regulated by multiple enzymes involving epigenetic modification. SNAI1
collaborates with multiple epigenetic enzyme complexes, such as DNA methyltransferases,
histone deacetylases, and histone methyltransferase and demethylase, in the transcriptional
regulation of CDH1. Recent studies suggest a crucial role of epigenetic alterations in the
regulation of SNAI1 and EMT markers.
Here, we summarize the regulation of SNAI1 with an emphasis on PTMs. Moreover,
we describe recent insights into the epigenetic mechanisms of SNAI1-induced cancer
metastasis, focusing on the cooperation of SNAI1 with epigenetic regulators.
2. Regulation of SNAI1
Expression of SNAI1 is governed at multiple levels from gene transcription, post-
transcriptional regulation, and translation to PTMs such as phosphorylation, ubiquitination,
acetylation, and sumoylation.
2.1. Structure of SNAI1
SNAI1 belongs to the SNAIL family which consists of SNAI1 (Snail), SNAI2 (Slug),
and SNAI3 (Smuc) [19]. The amino termini of SNAI1 contains the evolutionarily conserved
SNAI1/Gfi (SNAG) domain, which interacts with several co-repressor complexes or epige-
netic remodeling complexes (Figure 1). Drosophila SNAIL lacks the SNAG domain but has
a consensus PxDLSx motif and exerts their repressive function through the interaction with
the co-repressor c-terminal binding protein (CtBP) [19]. In the central region, a serine-rich
domain (SRD) is adjacent to the nuclear export sequence (NES) (Scheme 1). SRD controls
ubiquitination and proteasome degradation while NES is involved in the regulation of
its protein stability and subcellular translocation. The c-terminal zinc finger domain with
four C2H2-type zinc fingers is highly conserved. This domain mediates sequence-specific
interactions with their target DNA promoters containing an E-box sequence (CAGGTG).
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2.2. Transcriptional and Post-Transcriptional Regulation
A diverse repertoire of molecular mechanisms regulating SNAI1 at the transcriptional
level have been documented in a variety of organisms. Cytokines, chemokines, and
growth factors, such as tumor necrosis factor (TNFα), transforming growth factor (TGFβ),
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interleukin-6 (IL-6), fibroblast growth factors (FGF), epidermal growth factor (EGF), and
hepatocyte growth factor (HGF) [20], trigger an intracellular signaling cascade that leads
to the binding of a transcription factor to the SNAI1 promoter to regulate its expression.
Extensive evaluation of this regulation has been covered in other excellent reviews [21,22].
Interestingly, the expression of SNAI1 can also be regulated by other EMT-TFs. For example,
both SNAI1 and SNAI2 were upregulated under TGFβ stimulation [23]. Depletion of
SNAI2 increases SNAI1 expression and vice versa; this compensatory regulation could be
indispensable for EMT and cancer progression [24]. In addition, TWIST induces SNAI1
and the Twist-SNAI1 axis is critically involved in EMT and tumor metastasis [25].
Post-transcriptional control provides a fundamental regulatory mechanism for gene
expression. Besides regulation by microRNAs [26], SNAI1 transcript stability is also
regulated extensively. For example, recent work showed that upon activation of EGF
receptor, UDP-glucose 6-dehydrogenase (UGDH) is phosphorylated in human lung cancer
cells. Phosphorylated UGDH not only converts UDP-glucose to UDP-glucuronic acid but
also interacts with Hu antigen R (an RNA-binding protein that binds to short-lived mRNAs
to increase their stability). This interaction attenuates the UDP-glucose-mediated inhibition
and therefore enhances the stability of SNAI1 mRNA [27]. In addition, the mRNA of SNAI1
can be modified with N6-Methyladenosine (m6A) by the methyltransferase-like 3 (METTL3)
and YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) (m6A readers). m6A in
the coding sequence of SNAI1 triggers polysome-mediated translation of SNAI1 mRNA
in cancer cells [28]. The stability of SNAI1 mRNA is also enhanced by heterogeneous
nuclear ribonucleoprotein, which thus promotes invasion, metastasis, and EMT in breast
cancer [29].
2.3. Post-Translational Regulation
Because of their critical roles in cancer metastasis, much attention has focused on
the PTMs of SNAI1. PTMs function in the regulating protein stability, transcriptional
activity, and intracellular localization of SNAI1. Among the number of modifications,
phosphorylation and ubiquitination represent the best characterized and control a variety of
biological activities, such as apoptosis, transcription, metabolism, and stem cell properties.
Therefore, gaining deeper insight into the PTMs may help elucidate important steps in
cancer metastasis.
2.3.1. Phosphorylation Regulation
SNAI1 stability is extensively regulated by phosphorylation (Table 1). On one hand,
phosphorylation of SNAI1 promotes its proteasomal-mediated ubiquitination degradation.
Both casein kinase 1(CK1) and dual specificity tyrosine phosphorylation regulated kinase
2 (DYRK2)-mediated SNAI1 phosphorylation at serine (Ser) 104 act to prime phosphory-
lations that allow glycogen synthase kinase 3 β (GSK3β)-mediated phosphorylation at
Ser96 and Ser100, leading to β-TRCP-induced poly-ubiquitination and degradation [30,31].
Protein kinase D1 (PKD1)-mediated phosphorylation at Ser11 of SNAI1 facilitates F-box
protein 11 (FBXO11)-mediated SNAI1 degradation [32]. Under intact apical-basal polarity,
α protein kinase C (PKC) kinases promote degradation through phosphorylation of SNAI1
S249 [33]. On the other hand, some SNAI1 phosphorylations prevent its degradation.
Most commonly, the main mechanism that regulates SNAI1 stability is phosphorylation
at specific sites that reduce its affinity for GSK3β, thus blocking ubiquitination. For ex-
ample, phosphorylation of SNAI1 at Ser100 by ataxia-telangiectasia mutated (ATM) and
DNA-PKCs inhibits SNAI1 ubiquitination by reducing interaction with GSK3β [34,35].
Recently, it was shown that p38 stabilizes SNAI1 through phosphorylation at Ser107, which
suppresses DYRK2-mediated Ser104 phosphorylation and subsequent GSK3β-mediated
SNAI1 degradation [36]. However, stabilization of SNAI1 also occurs independent of
GSK3β. Protein kinase A (PKA) and CK2 have been characterized as the main kinases
responsible for in vitro SNAI1 phosphorylation at Ser11 and 92, respectively [37]. Phospho-
rylation of these two sites control SNAI1 stability and positively regulate SNAI1 repressive
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function and its interaction with the mSin3A corepressor. Alternatively, confinement of
SNAI1 to the nucleus prevents degradation. ERK2-mediated Ser82/Ser104 phosphoryla-
tion of SNAI1 leads to nuclear SNAI1 accumulation [38]. P21 (RAC1) activated kinase 1
(PAK1) and GRO-α phosphorylate SNAI1 on Ser246 and increase SNAI1′s accumulation in
the nucleus, which thus promotes transcriptional activity of SNAI1 [39–41]. Large tumor
suppressor kinase 2 (Lats2) phosphorylates SNAI1 at threonine (Thr)203 in the nucleus,
which prevents nuclear export, thereby supporting stabilization [42]. Recently, we also
found that serine/threonine kinase 39 (STK39) enhances SNAI1 stability by phosphory-
lation at Thr203 [43]. Notably, phosphorylation can be reversed by phosphatases. We
identified c-terminal domain phosphatase (SCP) as a specific phosphatase for SNAI1 [44].
SCP physically interacts with and stabilizes SNAI1 by direct dephosphorylation [44,45].
Table 1. Phosphorylation regulators involved in SNAI1.





















2.3.2. Ubiquitination and Deubiquitination
SNAI1′s ubiquitination and degradation are controlled by a number of F-box ligases,
including β-TRCP1/FBXW1, FBXL14, FBXL5, FBXO11, and FBXO45 [46]. Recently, more
E3 ligases have been discovered (Figure 2). F-box E3 ubiquitin ligase FBXO22 elicits an-
timetastatic effects by targeting SNAI1 ubiquitin-mediated proteasomal degradation in a
GSK3β phosphorylation-dependent manner [47]. Through a luciferase-based genome-wide
screening using small interfering RNA library against ~200 of E3 ligases and ubiquitin-
related genes, SOCS box protein SplA/ryanodine receptor domain and SOCS box contain-
ing 3 (SPSB3) was identified as a novel E3 ligase component [48]. SPSB3 targets SNAI1 to
promote polyubiquitination and degradation in response to GSK3β phosphorylation of
SNAI1. Through yeast two-hybrid screening, the carboxyl terminus of Hsc70-interacting
protein (CHIP) was identified as a novel SNAI1 ubiquitin ligase that interacts with SNAI1
to induce ubiquitin-mediated proteasomal degradation [49]. Recently, it was reported that
SNAI1 was monoubiquitinated by the ubiquitin-editing enzyme A20. This monoubiquity-
lation of SNAI1 reduces the affinity of SNAI1 for GSK3β, and thus SNAI1 is stabilized in
the nucleus [50].
Deubiquitinases (DUBs) counteract the SNAI1 degradation process to maintain a high
level of SNAI1 protein in cancer cells. We recently identified DUB3 as a SNAI1 deubiq-
uitinase that interacts with and stabilizes SNAI1 [51]. Independent research indicated
that DUB3 is a target of cyclin-dependent kinase (CDK)4/6, and CDK4/6-mediated ac-
tivation of DUB3 is essential to deubiquitinate and stabilize SNAI1 [52]. Resistance to
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platinum-based chemotherapy is a common event associated with tumor dissemination
and metastasis in cancer patients. Upon platinum treatment, the ubiquitin-specific protease
1 (USP1) is phosphorylated by ATM and RAD3-related (ATR) and binds to SNAI1. Then,
USP1 de-ubiquitinates and stabilizes SNAI1 expression, conferring resistance to platinum,
increased stem cell-like features, and metastatic ability [53]. USP29 can be induced by major
EMT and metastatic-inducing factors such as TGFβ, TNFα, and hypoxia. This protease
enhances the interaction of SNAI1 and SCP1, and results in simultaneous dephosphory-
lation and de-ubiquitination of SNAI1 and thereafter cooperative prevention of SNAI1
degradation [54]. TGFβ also induces USP27X expression, which increases SNAI1 stability
by deubiquitination [55]. Recently, more deubiquitinases have been identified. Eukaryotic
translation initiation factor 3 subunit H (EIF3H), OTU deubiquitinase, ubiquitin aldehyde
binding 1(OTUB1), USP3, proteasome 26S subunit, Non-ATPase 14 (PSMD14), USP26,
USP36, USP37 also target SNAI1 for de-ubiquitination and stabilization (Figure 2) [56–61].
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Figure 2. The ubiquitination and de-ubiquitination of SNAI1. SNAI1 is degraded by multiple E3 lig-
ases. By contrast, de-ubiquitinases counteract E3 ligase activity and prevent SNAI1 degradation. USP:
ubiquitin-specific protease; OTUB1: OTU deubiquitinase, ubiquitin aldehyde binding 1; PSMD14:
proteasome 26S subunit, Non-ATPase 14; EIF3H: eukaryotic translation initiation factor 3 subunit H;
DUB: deubiquitinase; UPS: ubiquitin/proteasome system; FBXW1: F-box/WD repeat-containing
protein 1; FBXL: F-box and leucine rich repeat pr tein; FBXO: F-boxes other; SPSB3: SplA/ryanodine
rec ptor domain and SOCS box containing 3; CHIP: carboxy-terminus of Hsc70 interacting protein.
2.3.3. Other Post-Translational Regulation
Beyond the well-characterized PTMs of phosphorylation and ubiquitination, at least
three other PTMs are involved in regulating SNAI1 protein abundance and activity. First,
the sumoylation pathway is very similar to its biochemical analog, ubiquitylation, and
regulates diverse cellular processes including transcription and protein stability, chromo-
some organization, DNA repair, and other cellular processes. TGFβ induces sumoylation
of SNAI1 at its lysine (K) 234 residue, which is critical for the EMT-activating function of
SNAI1 [62]. Second, the O-linked β-N-acetylglucosamine (O-GlcNAc) modification is a
monosaccharide addition. SNAI1 is subject to O-GlcNAc at Ser112 under hyperglycemic
conditions [63]. This modification leads to stabilization of SNAI1 by inhibition of GSK3β-
mediated phosphorylation. Consequently, the O-GlcNAc SNAI1 promotes EMT. Finally,
SNAI1 is also acetylated by the histone acetyltransferase adenovirus E1A-associated protein
(p300) and CREB binding protein (CBP), two key transcriptional coactivators implicated
in a multitude of cellular processes including cancer progression. CBP and p300 interact
with SNAI1 to acetylate SNAI1 at K146 and K187, which consequently reduces SNAI1
ubiquitination and thus enhances its protein stability [64] (Figure 3).
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3. The Interplay between SNAI1 and Epigenetic Regulators in Tumor Metastasis
Because EMT is a reversible and transient process, as well as having reversibility of
the epigenetic marks and the enzymatic nature of the regulators, EMT-TFs and chromatin-
remodeling enzymes are intimately connected (Figure 3). During tumor metastasis, SNAI1
recruits epigenetic regulators to the CDH1 promoter, thus repressing its expression. Epi-
genetic alterations also play a crucial role in SNAI1 expression. The interplay between
SNAI1 and epigenetic regulators indicate the complexity of epigenetic mechanisms and
the potentially crucial role of histone modifications for regulating SNAI1.
3.1. S AI1 and A ethylation
ethylation involves a covalent attachment of a methyl group to cytosine
residues at CpG-rich dinucleotide sequences through ethyltransferases ( s).
pon induction of EMT, hypermethylation of the CDH1 promoter through DNMTs, which
are recruited by EMT-TFs, is constantly observed in a wide variety of canc r cells. For exam-
ple, SNAI1 interacts with DNMT3A to repress CDH1 expression via DNA hypermethyla-
tion and histone mo ifications of H3K9me2 and H3K27me3 in gastric cancer [65]. Previous
research also indicated that DNMT1 was implicated in cell metas asis, such that downregu-
lation r i hibition of DNMT1 c uld facilitate the metastasis of cancer cell [66]. DNMT1
can decrease the expression of CDH1 by increasing promot r methylati n. Int restingly,
DNMT1 can also act on CDH1 expression independent of its catalytic activity [67]. DNMT1
interacts with SNAI1 to prevent its interaction with the CDH1 promoter; this interaction
leads to full CDH1 expression. Furthermore, DNMT1 is recruited to the SNAI1 promoter by
AT-rich interactive domain-containing protein 2 (ARID2), a subunit of SWI/SNF chromatin
remodeling complex. This complex increases the DNA methylation and suppresses SNAI1
transcription, leading to a repression of EMT. During hepatocellular carcinoma progression,
loss/mutation of ARID2 impairs recruitment of DNMT1 to the SNAI1 promoter. As a
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result of decreased methylation at the SNAI1 promoter, there is an upregulation of SNAI1
expression that ultimately promotes EMT [68]. These results suggest that DNMT1 plays a
cellular context-dependent role in tumor metastasis. Protein arginine methyltransferase
(PRMT) 5 is a type II protein arginine methyltransferase. PRMT5 physically associates
with SNAI1 and the NuRD (MAT1) complex to form a transcriptionally repressive complex
that catalyzes a simultaneous histone demethylation and deacetylation. In addition, this
complex also inhibits tet methylcytosine dioxygenase 1 (TET1) and contributes to DNA
hypermethylation [69].
3.2. SNAI1 and Histone Modification
3.2.1. Acetylation
A variety of transcriptional co-activating complexes, which contain lysine acetyltrans-
ferase, catalyze lysine acetylation of histone tails. Because acetylation masks the positive
charge on lysine residues and weakens the DNA–histone association and relaxes the chro-
matin structure, histone acetylation is often associated with gene activation. SNAI1 recruits
the p300 activator complex to the VEGF and Sox2 promoters to stimulate their expression,
leading to endothelium generation and tumor growth [70].
3.2.2. Deacetylation
Histone deacetylation by histone deacetylase (HDAC) is believed to restrict gene
transcription because it reveals the positive charge of lysine and permits the DNA–histone
interaction. HDACs, in particular HDAC1 and HDAC2, are often recruited by EMT-TFs
to gene promoter regions and form protein complexes to deacetylate histones and silence
expression of epithelial gene factors. For instance, SNAI1 mediates recruitment of the
HDAC1/2 that contain Sin3A or NuRD repressor complexes to inhibit CDH1 expression
by deacetylation of histones H3 and H4. This effect was abolished by treatment with the
HDAC inhibitor Trichostatin A (TSA) [71,72]. Interestingly, HDAC2 can also be recruited by
the HOP homeobox to epigenetically inhibit SNAI1 transcription, leading to the enhanced
histone H3K9 deacetylation, which subsequently suppresses tumor progression [73]. Sim-
ilarly, HDAC1 can be recruited by SATB homeobox 2 (SATB2) to the SNAI1 promoter,
repressing SNAI1 transcription and inhibiting EMT [74]. Recently, it has been reported that
HDAC8 increases the protein stability of SNAI1 via AKT/GSK3β signals [75]. HDAC8
interacts with AKT1 to decrease acetylation while increasing its phosphorylation, which
further increases Ser9-phosphorylation of GSK3β. Sirt6, the class III histone deacetylates,
functions as an NAD+-dependent histone deacetylase. Sirt6 interacts with p65 and attenu-
ates NF-kB regulated SNAI1 expression by removing acetyl residues of histone H3K9 and
H3K56 in the promoter regions of SNAI1 [76].
3.2.3. Acetylation Readers
The bromodomain-containing proteins (BRDs) are acetylation readers that bind to
ε-N-aminoacetyl groups of nucleosomal histone lysines and recruit histone modifiers and
transcriptional/remodeling factors to gene promoters; these processes promote upregula-
tion or repression of gene expression. Ever increasing studies in different cancer cells have
demonstrated the contribution of BRDs to cancer progression [77]. For instance, BRD4
interacts with SNAI1 if certain K146 and K187 are acetylated. This interaction prevents
recognition of SNAI1 by its E3 ubiquitin ligases FBXL14 and β-TrCP1, thereby inhibiting
SNAI1 polyubiquitination and proteasomal degradation [78]. In addition, BRD4 increases
SNAI1 expression by diminishing the PKD1-mediated proteasome degradation pathway.
BRD4 inhibition suppresses the expression of Gli1, which is required for transcriptional
activation of SNAI1, indicating that BRD4 controls malignancy of breast cancer cells via
both transcriptional and post-translational regulation of SNAI1 [79]. Therefore, inhibition
of BRD4 is a promising therapeutic approach for cancer patients with metastatic lesions.
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3.2.4. Methylation
Histone lysine methylation is catalyzed by lysine methyltransferases, which directly
recruit or inhibit the recruitment of histone-binding proteins. Usually, H3K9 and H3K27
methylation is associated with transcriptional repression, while H3K79 is often linked with
gene activation. G9a is responsible for the transcriptionally repressive modification of
H3K9. In aggressive lung cancer cells, G9a is preferentially expressed, and its elevated
expression correlates with poor prognosis. G9a represses a cell adhesion molecule EPCAM,
which stimulates EMT and cancer metastasis by catalyzing H3K9me2 on its promoter [80].
In breast cancer cells, SNAI1 recruits G9a to the CDH1 promoter for transcription silencing.
Therefore, inhibition of G9a reduces promoter H3K9me2 as well as DNA methylation
which abrogates EMT and tumor metastasis [81]. Meanwhile, SNAI1 also interacts with
Suv39H1, a histone methyltransferase for the trimethylation of histone H3 at lysine K9
(H3K9me3) to the CDH1 promoter to repress its transcription. EZH2, the catalytic subunit
of the polycomb repressive complex 2 (PRC2), promotes transcriptional silencing of CDH1
by H3K27me3 [82,83]. EZH2 can interact with HDAC1/HDAC2 in association with SNAI1
to form a complex that represses CDH1 expression [84]. DOT1L catalyzes the methylation
of an active transcription mark histone H3K79, which is crucial for tumor development [85].
In breast cancers, DOT1L forms a transcriptionally active complex with c-Myc and p300
to facilitate H3K79 methylation and acetylation in the promoter regions of SNAI1 that
enhances SNAI1 de-repression, consequently promoting EMT [86].
3.2.5. Demethylation
Histone lysine-specific demethylase 1 (LSD1) functions as an epigenetic regulator by
removing methyl groups on the transcription-activating H3K4 or repressing H3K9 residues
through an amine oxidase reaction [87,88]. LSD1 takes part in a variety of chromatin-
remodeling protein complexes to regulate tumor progression. We found that the amine
oxidase domain of LSD1 interacts with the SNAG domain of SNAI1 [89]. SNAI1 recruits
LSD1 and forms the SNAI1-LSD1-CoREST complex to repress CDH1 expression and en-
hance cell migration [89]. Another study indicated that SNAI1 recruits LSD1 on epithelial
gene promoters for H3K4me2 demethylation, thereby silencing their expression and pro-
moting EMT [90]. The chromatin remodeling factor Jumonji C (JmjC) domain-containing
protein 3 (JMJD3, also known as KDM6B) is a α-ketoglutarate-dependent demethylase
which is responsible for the demethylation of di- and trimethyllysine 27 (H3K27m2/3)
on histone H3. JMJD3 demethylates H3K27m3 at the SNAI1 promoter to activate the
transcription of SNAI1 during TGFβ-induced EMT [91]. In addition, JMJD1A also tran-
scriptionally activates SNAI1 expression via H3K9me1 and H3K9me2 demethylation at its
promoter [92].
4. Potential Pharmacological Inhibitors of SNAI1
Given the important role of SNAI1 in driving cancer progression, targeting SNAI1
would be an attractive anticancer therapeutic approach. However, the development of
small molecules to inhibit SNAI1′s functions is hindered as there is no clear “ligand-binding
domain” for targeting SNAI1. However, other strategies have been successfully attempted.
First, the E-box, a SNAI1-binding site, was chosen as a target. A Co(III) complex conju-
gated to a CAGGTG hexanucleotide was synthesized. This complex binds to SNAI1 and
prevents any interaction with DNA, thus reducing the invasive potential of tumor cells [93].
Second, the SNAI1-p53 complex acts as a target. Two leader compounds, GN25 and GN29,
increase the expression of p53 and uncouple it from SNAI1. These two compounds se-
lectively inhibit K-ras mutated cells [94]. Third, the LSD1-SNAI1 complex was chosen as
a target. Inhibiting its interactions blocks cancer cell invasion [95,96]. Fourth, CYD19, a
small-molecule compound, binds to SNAI1 and disrupts the SNAI1 interaction with p300,
leading to SNAI1 degradation [97]. CYD19 impairs EMT-associated tumor invasion and
metastasis by reversing SNAI1-driven EMT; this finding provides evidence that pharmaco-
logic interference with SNAI1 acetylation may exert potent therapeutic effects in patients
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with cancer. Finally, chemical classes of synthetic and natural compounds affecting the
transcriptional activity and expression of SNAI1 have already been characterized. For
example, disulfiram inhibits cell migration, invasion, and growth of tumor grafts through
the ERK/NF-κB/SNAI1 signaling pathway [98]. The proteasome inhibitor, NPI-0052,
also inhibits SNAI1 expression via inhibition of NF-kB [99]. In all, targeting the SNAI1
complex or suppression of SNAI1 expression is one major approach to specifically inhibit
SNAI1 activity.
Proteolysis-targeting chimeras (PROTACs) that hijack the ubiquitin-proteasome sys-
tem for targeted protein degradation have expanded significantly in years [100]. This
technology circumvents some of the limitations associated with traditional small-molecule
therapeutics. PROTAC consists of a ligand for an E3 ligase and a ligand for a protein of inter-
est (POI) connected by a chemical linker to form a ternary complex. In 2021, TRAnscription
Factor Targeting Chimeras (TRAFTACs) technology was developed. The TRAFTAC system
is composed of a HaloTag-fused dCas9 protein and a chimeric oligonucleotide that can
bind transcription factor of interest (TOI) and dCas9 simultaneously [101]. This system
labels the TOI with ubiquitin which then degrades the TOI by proteasomal machinery. This
strategy was applied to target several transcription factors including E2F1 and NF-kB [102].
It will be attractive to design a TRAFTAC targeting SNAI1.
5. Conclusions and Perspective
SNAI1 as the key EMT regulator plays important roles in invasion and metastasis. The
molecular events mediated by SNAI1 are of interest as therapeutic targets, in particular for
resistant metastatic tumors. Although direct targeting of SNAI1 is unsuccessful, identifying
inhibitors for PTMs of SNAI1 hold significant potential, and thus are a high priority in
the development of future cancer treatments. Indeed, many pharmacological approaches,
including chemical inhibitors and monoclonal antibodies that target these modification
enzymes including deubiquitinase and kinase, have been devised and show promise for
the treatment of tumor metastasis [103]. Furthermore, identification of SNAI1′s post-
transcriptional and PTMs is crucial given that these changes could be identified in the
primary tumor before metastasis occurs. Such knowledge would facilitate better prediction
of patients who have genotypes that are more likely to follow an aggressive clinical course
and who are prone to development of metastases.
In addition, because of the intimate connection between SNAI1 and chromatin-
remodeling enzymes, targeting the epigenetic enzymes to reverse the EMT process is
also an efficient and promising approach [104]. Indeed, abundant pre-clinical and clinical
studies examining the effects of these epigenetic enzyme inhibitors alone or in combination
with other anti-cancer agents are under development [105]. However, the impact of these
epigenetic alternations on tumor metastasis differs greatly in various types of cancers.
Therefore, it is urgent to comprehensively understand the mechanisms of action and roles
of epigenetic modulations on EMT in different cancer types. These detailed mechanisms
of epigenetic regulation in tumor metastasis will provide a bright future for the use of an
efficient and specific “epigendrug” as one of the important therapeutic strategies in the
fight against tumor metastasis.
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